Detailed comparison of the efficacy and side effects of ponatinib and orebatinib

Ponatinib and olverembatinib (Olverembatinib) both belong to the third generation tyrosine kinase inhibitors (TKI), mainly used to treat chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients, especially those with drug resistance or mutantBCR-ABL positive. Ponatinib was initially developed for the T315I mutation and has broad-spectrum BCR-ABL inhibitory capabilities, while orebatinib is targeting< The /span>T315I mutation also shows outstanding efficacy in efficacy. At the same time, some clinical studies have shown good tolerance and efficacy in patients with CML chronic phase.

In terms of efficacy, both can effectively inhibitBCR-ABL mutant tyrosine kinase, thereby preventing leukemia cell proliferation. Clinical data of ponatinib show that patients with T315I mutations have a higher complete molecular response (CMR) rate, but hematological and molecular indicators need to be closely monitored. Orapatinib's clinical studies in China have shown that its major molecular response rate (MMR) for chronic phase CML and accelerated phase CML is similar to that of ponatinib, but the efficacy of some patients is maintained longer, and the effect is stable in controlling mutant leukemia.

In terms of side effects, common adverse reactions of ponatinib include thrombotic events, cardiovascular complications, hypertension, and pancreatitis. Some patients may experience thrombocytopenia and abnormal liver function. Therefore, cardiovascular and laboratory indicators need to be strictly monitored during use. The adverse reactions of orebatinib are relatively mild. Although hematological toxicity, rash and mild liver function abnormalities may also occur, the overall incidence of thrombosis and cardiovascular events is lower, the tolerance is better, and it is more suitable for long-term maintenance treatment.

Taken together, both ponatinib and orebatinib show good efficacy in patients with drug-resistant and mutant BCR-ABL. However, ponatinib has relatively more severe side effects and requires strict monitoring of cardiovascular risks. Orelabatinib has advantages in terms of safety and tolerability, and is especially suitable for patients who are sensitive to cardiovascular risks or require long-term medication. During clinical selection, a comprehensive assessment should be based on the patient's specific condition, mutation type, and tolerance to formulate an individualized treatment plan.

Reference materials:https://www.drugs.com/